Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors
Identifieur interne : 003F76 ( Main/Exploration ); précédent : 003F75; suivant : 003F77Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors
Auteurs : Céline Gagnon [Canada] ; Baltazar Gomez-Mancilla [Canada] ; Rudolf Markstein [Suisse] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada]Source :
- Progress in Neuropsychopharmacology & Biological Psychiatry [ 0278-5846 ] ; 1995.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Singe.
English descriptors
- KwdEn :
- Animal, Animals, Antiparkinson agent, Autoradiography, Behavior, Animal (drug effects), Brain Chemistry (drug effects), Bromocriptine (pharmacology), Bromocryptine, Chemotherapy, D1 Dopamine receptor, D2 Dopamine receptor, Dopamine Agents (toxicity), Dopamine Agonists (pharmacology), Dopamine agonist, Drug combination, Ergot derivatives, Female, Indoles (pharmacology), MPTP Poisoning, Macaca fascicularis, Mechanism of action, Monkey, Neostriatum (drug effects), Neostriatum (metabolism), Ovariectomy, Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (drug therapy), Parkinson Disease, Secondary (metabolism), Parkinson disease, Phenanthridines (pharmacology), Receptors, Dopamine D1 (agonists), Receptors, Dopamine D2 (drug effects), Subcutaneous administration, Treatment efficiency.
- MESH :
- chemical , agonists : Receptors, Dopamine D1.
- chemical , drug effects : Receptors, Dopamine D2.
- chemical , pharmacology : Bromocriptine, Dopamine Agonists, Indoles, Phenanthridines.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Behavior, Animal, Brain Chemistry, Neostriatum.
- drug therapy : Parkinson Disease, Secondary.
- metabolism : Neostriatum, Parkinson Disease, Secondary.
- chemical , toxicity : Dopamine Agents.
- Animals, Autoradiography, Female, MPTP Poisoning, Macaca fascicularis, Ovariectomy.
Abstract
1. 1. Eleven monkeys were administered N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): eight were treated with bromocriptine for one week and then CY 208–243 (four monkeys) or saline (four monkeys) was added to the bromocriptine treatment. 2. 2. Addition of CY 208–243 increased the therapeutic response observed with the ergot alone without inducing dyskinesia. 3. 3. Following MPTP, [3H]-SCH 23390 specific binding to D-1 receptors as well as [3H]-spiperone and [3H]-N-n-propylnorapomorphine specific binding to D-2 receptors increased in posterior striatum compared to control animals, whereas [3H]-SKF 38393 binding to D-1 receptors tended to decrease. 4. 4. Dopamine receptor density was unchanged in anterior striatum of untreated MPTP-monkeys. 5. 5. In the posterior striatum, both dopaminergic treatments decreased towards control values [3H]-SCH 23390, [3H]-spiperone and [3H]-N-n-propylnorapomorphine binding whereas they did not significantly change [3H]-SKF 38393 specific binding. [3H]-SKF 38393 specific binding increased in anterior striatum of bromocriptine-treated MPTP-monkeys, compared to untreated MPTP-animals, and this increase was abolished in animals treated with bromocriptine + CY 208–243. 6. 6. The present study shows that in MPTP-monkeys, treated or not with DA agonists, the D1 and D2 receptor changes are concentrated in the posterior striatum and that denervation appears to cause a shift from the high to the low affinity agonist state of D1 receptors but not for the D2 subtype.
Url:
DOI: 10.1016/0278-5846(95)00110-H
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000F93
- to stream Istex, to step Curation: 000F93
- to stream Istex, to step Checkpoint: 001950
- to stream Main, to step Merge: 004698
- to stream PascalFrancis, to step Corpus: 000F57
- to stream PascalFrancis, to step Curation: 000F66
- to stream PascalFrancis, to step Checkpoint: 000E66
- to stream Main, to step Merge: 004823
- to stream PubMed, to step Corpus: 001916
- to stream PubMed, to step Curation: 001916
- to stream PubMed, to step Checkpoint: 001916
- to stream Ncbi, to step Merge: 002519
- to stream Ncbi, to step Curation: 002519
- to stream Ncbi, to step Checkpoint: 002519
- to stream Main, to step Merge: 004633
- to stream Main, to step Curation: 003F76
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors</title><author><name sortKey="Gagnon, Celine" sort="Gagnon, Celine" uniqKey="Gagnon C" first="Céline" last="Gagnon">Céline Gagnon</name></author><author><name sortKey="Gomez Mancilla, Baltazar" sort="Gomez Mancilla, Baltazar" uniqKey="Gomez Mancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name></author><author><name sortKey="Markstein, Rudolf" sort="Markstein, Rudolf" uniqKey="Markstein R" first="Rudolf" last="Markstein">Rudolf Markstein</name></author><author><name sortKey="J Bedard, Paul" sort="J Bedard, Paul" uniqKey="J Bedard P" first="Paul" last="J. Bédard">Paul J. Bédard</name></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7908F0DDDD71AB73353787948ED454A99EF7EB74</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1016/0278-5846(95)00110-H</idno><idno type="url">https://api-v5.istex.fr/document/7908F0DDDD71AB73353787948ED454A99EF7EB74/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000F93</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000F93</idno><idno type="wicri:Area/Istex/Curation">000F93</idno><idno type="wicri:Area/Istex/Checkpoint">001950</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001950</idno><idno type="wicri:doubleKey">0278-5846:1995:Gagnon C:effect:of:adding</idno><idno type="wicri:Area/Main/Merge">004698</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:95-0533204</idno><idno type="wicri:Area/PascalFrancis/Corpus">000F57</idno><idno type="wicri:Area/PascalFrancis/Curation">000F66</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000E66</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000E66</idno><idno type="wicri:doubleKey">0278-5846:1995:Gagnon C:effect:of:adding</idno><idno type="wicri:Area/Main/Merge">004823</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8588064</idno><idno type="wicri:Area/PubMed/Corpus">001916</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001916</idno><idno type="wicri:Area/PubMed/Curation">001916</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001916</idno><idno type="wicri:Area/PubMed/Checkpoint">001916</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001916</idno><idno type="wicri:Area/Ncbi/Merge">002519</idno><idno type="wicri:Area/Ncbi/Curation">002519</idno><idno type="wicri:Area/Ncbi/Checkpoint">002519</idno><idno type="wicri:doubleKey">0278-5846:1995:Gagnon C:effect:of:adding</idno><idno type="wicri:Area/Main/Merge">004633</idno><idno type="wicri:Area/Main/Curation">003F76</idno><idno type="wicri:Area/Main/Exploration">003F76</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors</title><author><name sortKey="Gagnon, Celine" sort="Gagnon, Celine" uniqKey="Gagnon C" first="Céline" last="Gagnon">Céline Gagnon</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>School of Pharmacy, Laval University, Quebec, and Department of Molecular Endocrinology, Laval University Medical Center, Ste-Foy, Qc</wicri:regionArea><wicri:noRegion>Qc</wicri:noRegion></affiliation></author><author><name sortKey="Gomez Mancilla, Baltazar" sort="Gomez Mancilla, Baltazar" uniqKey="Gomez Mancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, and Department of Pharmacology, Laval University, Faculty of Medicine, Quebec, Qc</wicri:regionArea><wicri:noRegion>Qc</wicri:noRegion></affiliation></author><author><name sortKey="Markstein, Rudolf" sort="Markstein, Rudolf" uniqKey="Markstein R" first="Rudolf" last="Markstein">Rudolf Markstein</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Preclinical Research Sandoz, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="J Bedard, Paul" sort="J Bedard, Paul" uniqKey="J Bedard P" first="Paul" last="J. Bédard">Paul J. Bédard</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, and Department of Pharmacology, Laval University, Faculty of Medicine, Quebec, Qc</wicri:regionArea><wicri:noRegion>Qc</wicri:noRegion></affiliation></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><affiliation></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>School of Pharmacy, Laval University, Quebec, and Department of Molecular Endocrinology, Laval University Medical Center, Ste-Foy, Qc</wicri:regionArea><wicri:noRegion>Qc</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Progress in Neuropsychopharmacology & Biological Psychiatry</title><title level="j" type="abbrev">PNP</title><idno type="ISSN">0278-5846</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1995">1995</date><biblScope unit="volume">19</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="667">667</biblScope><biblScope unit="page" to="676">676</biblScope></imprint><idno type="ISSN">0278-5846</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0278-5846</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term><term>Animals</term><term>Antiparkinson agent</term><term>Autoradiography</term><term>Behavior, Animal (drug effects)</term><term>Brain Chemistry (drug effects)</term><term>Bromocriptine (pharmacology)</term><term>Bromocryptine</term><term>Chemotherapy</term><term>D1 Dopamine receptor</term><term>D2 Dopamine receptor</term><term>Dopamine Agents (toxicity)</term><term>Dopamine Agonists (pharmacology)</term><term>Dopamine agonist</term><term>Drug combination</term><term>Ergot derivatives</term><term>Female</term><term>Indoles (pharmacology)</term><term>MPTP Poisoning</term><term>Macaca fascicularis</term><term>Mechanism of action</term><term>Monkey</term><term>Neostriatum (drug effects)</term><term>Neostriatum (metabolism)</term><term>Ovariectomy</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (drug therapy)</term><term>Parkinson Disease, Secondary (metabolism)</term><term>Parkinson disease</term><term>Phenanthridines (pharmacology)</term><term>Receptors, Dopamine D1 (agonists)</term><term>Receptors, Dopamine D2 (drug effects)</term><term>Subcutaneous administration</term><term>Treatment efficiency</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Receptors, Dopamine D1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine D2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Bromocriptine</term><term>Dopamine Agonists</term><term>Indoles</term><term>Phenanthridines</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term><term>Brain Chemistry</term><term>Neostriatum</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Neostriatum</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Dopamine Agents</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Autoradiography</term><term>Female</term><term>MPTP Poisoning</term><term>Macaca fascicularis</term><term>Ovariectomy</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animal</term><term>Antiparkinsonien</term><term>Association médicamenteuse</term><term>Bromocriptine</term><term>CY 208 243</term><term>Chimiothérapie</term><term>Efficacité traitement</term><term>Ergot dérivé</term><term>Mécanisme action</term><term>Parkinson maladie</term><term>Récepteur dopaminergique D1</term><term>Récepteur dopaminergique D2</term><term>Singe</term><term>Stimulant dopaminergique</term><term>Voie souscutanée</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">1. 1. Eleven monkeys were administered N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): eight were treated with bromocriptine for one week and then CY 208–243 (four monkeys) or saline (four monkeys) was added to the bromocriptine treatment. 2. 2. Addition of CY 208–243 increased the therapeutic response observed with the ergot alone without inducing dyskinesia. 3. 3. Following MPTP, [3H]-SCH 23390 specific binding to D-1 receptors as well as [3H]-spiperone and [3H]-N-n-propylnorapomorphine specific binding to D-2 receptors increased in posterior striatum compared to control animals, whereas [3H]-SKF 38393 binding to D-1 receptors tended to decrease. 4. 4. Dopamine receptor density was unchanged in anterior striatum of untreated MPTP-monkeys. 5. 5. In the posterior striatum, both dopaminergic treatments decreased towards control values [3H]-SCH 23390, [3H]-spiperone and [3H]-N-n-propylnorapomorphine binding whereas they did not significantly change [3H]-SKF 38393 specific binding. [3H]-SKF 38393 specific binding increased in anterior striatum of bromocriptine-treated MPTP-monkeys, compared to untreated MPTP-animals, and this increase was abolished in animals treated with bromocriptine + CY 208–243. 6. 6. The present study shows that in MPTP-monkeys, treated or not with DA agonists, the D1 and D2 receptor changes are concentrated in the posterior striatum and that denervation appears to cause a shift from the high to the low affinity agonist state of D1 receptors but not for the D2 subtype.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Suisse</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Gagnon, Celine" sort="Gagnon, Celine" uniqKey="Gagnon C" first="Céline" last="Gagnon">Céline Gagnon</name></noRegion><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><name sortKey="Gomez Mancilla, Baltazar" sort="Gomez Mancilla, Baltazar" uniqKey="Gomez Mancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name><name sortKey="J Bedard, Paul" sort="J Bedard, Paul" uniqKey="J Bedard P" first="Paul" last="J. Bédard">Paul J. Bédard</name></country><country name="Suisse"><noRegion><name sortKey="Markstein, Rudolf" sort="Markstein, Rudolf" uniqKey="Markstein R" first="Rudolf" last="Markstein">Rudolf Markstein</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F76 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003F76 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7908F0DDDD71AB73353787948ED454A99EF7EB74
|texte= Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors
}}
| This area was generated with Dilib version V0.6.29. |  |